Your AI-Trained Oncology Knowledge Connection!

Firas El Chaer, MD

home / authors / firas-el-chaer-md

Articles

Firas El Chaer, MD, of UVA Health

Dr. El Chaer on the Role of Next-Generation Sequencing in MPNs

Firas El Chaer, MD
December 4th 2020

Firas El Chaer, MD, discusses the role of next-generation sequencing (NGS) in myeloproliferative neoplasms.

Read More

Firas El Chaer, MD

Dr. El Chaer on the Potential for Combination Strategies With Ruxolitinib in MPNs

Firas El Chaer, MD
November 25th 2020

Firas El Chaer, MD, discusses the potential utility of combination strategies with ruxolitinib in patients with myeloproliferative neoplasms.

Read More

Firas El Chaer, MD, of UVA Health

Dr. El Chaer on the Limitations of JAK Inhibitors in Myelofibrosis

Firas El Chaer, MD
November 17th 2020

Firas El Chaer, MD, discusses the limitations of JAK inhibitors in myelofibrosis.

Read More

Latest Updated Articles

RLY-2608
Published: January 22nd 2025 | Updated: February 14th 2025
Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor, in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial
Tagraxofusp Achieves Anti-tumor Activity With Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
Published: February 11th 2025 | Updated: February 14th 2025
Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
2 expert is featured in this series.
Published: December 24th 2024 | Updated: January 28th 2025
Brief Overview of Synovial Sarcoma: What It Is, Clinical Presentation and Diagnosis
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Published: December 17th 2024 | Updated: January 16th 2025
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Ropeginterferon Alfa-2b in Essential Thrombocytopenia | Image Credit: © Tatiana Shepeleva - stock.adobe.com
Published: January 6th 2025 | Updated: January 8th 2025
Second-Line Ropeginterferon Alfa-2b Boosts Responses in Essential Thrombocythemia
OncLive co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for medical oncologists to look out for at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Medical Oncologists: The Show and After Show